Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Feature|Articles|June 15, 2026
Midyear cataract check-in: What 2026 has brought to the OR and beyond
Author(s)Lucia Gambuzza
A midyear recap of the cataract-related news Ophthalmology Times has covered in 2026
Advertisement
Advertisement
June marks Cataract Awareness Month—a reminder that cataracts remain the leading cause of preventable blindness worldwide, and that the clinical and surgical landscape is far from static. In the first half of 2026, Ophthalmology Times has covered everything from a safety alert in the OR to new postoperative therapies and emerging noninvasive treatment options. Here is where things stand at the midyear mark.
Related to this article
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Advertisement
Advertisement